Persistent bone marrow failure with dysplastic features following pentostatin therapy for hairy cell leukaemia.
Myelodysplastic syndromes (MDS) have rarely been reported after treatment with nucleoside analogues, and mainly in patients who have also received alkylating agents. We report a patient who developed MDS (refractory anaemia with ring sideroblasts) after treatment with pentostatin (deoxycoformycin) alone.
Department of Haematology, St Mary's Hospital, London, UK.
E
E
Psiachou-Leonard
B J
BJ
Bain
D058892:Adenosine Deaminase Inhibitors; D000368:Aged; D000753:Anemia, Refractory / Q000139:chemically induced*; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D001803:Blood Transfusion; D001853:Bone Marrow / Q000473:pathology; D003131:Combined Modality Therapy; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006412:Hematopoietic Stem Cells / Q000473:pathology; D006801:Humans; D007943:Leukemia, Hairy Cell / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D009503:Neutropenia / Q000139:chemically induced*; D015649:Pentostatin / Q000009:adverse effects* / Q000627:therapeutic use; D012074:Remission Induction
D058892:Adenosine Deaminase Inhibitors; D000903:Antibiotics, Antineoplastic; D004791:Enzyme Inhibitors; D015649:Pentostatin